2.89 USD
▲+0.10+3.58%
盘后 2.92 +0.90%
2026-09-15
市值
$188.75M
市盈率
—
EPS
-1.64
股息率
—
52 周区间
1.21 – 3.60
成交量
359.31K
Beta
0.38
目标价
7.40
52W 低 1.2152W 高 3.60
价格走势
公司简介
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development o...